These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1142 related articles for article (PubMed ID: 18095777)
21. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies. Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175 [TBL] [Abstract][Full Text] [Related]
22. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals. Hirsch M; O'donnell J; Olsson A Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052 [TBL] [Abstract][Full Text] [Related]
23. Effects of rosuvastatin and atorvastatin compared over 52 weeks of treatment in patients with hypercholesterolemia. Olsson AG; Istad H; Luurila O; Ose L; Stender S; Tuomilehto J; Wiklund O; Southworth H; Pears J; Wilpshaar JW; Am Heart J; 2002 Dec; 144(6):1044-51. PubMed ID: 12486429 [TBL] [Abstract][Full Text] [Related]
24. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category. Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597 [TBL] [Abstract][Full Text] [Related]
25. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study. Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610 [TBL] [Abstract][Full Text] [Related]
26. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640 [TBL] [Abstract][Full Text] [Related]
27. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial). Lloret R; Ycas J; Stein M; Haffner S; Am J Cardiol; 2006 Sep; 98(6):768-73. PubMed ID: 16950182 [TBL] [Abstract][Full Text] [Related]
28. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice. Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726 [TBL] [Abstract][Full Text] [Related]
29. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial. Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813 [TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. Brown WV; Bays HE; Hassman DR; McKenney J; Chitra R; Hutchinson H; Miller E; Am Heart J; 2002 Dec; 144(6):1036-43. PubMed ID: 12486428 [TBL] [Abstract][Full Text] [Related]
31. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (< 70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Betteridge DJ; Gibson JM; Sager PT Am J Cardiol; 2007 Oct; 100(8):1245-8. PubMed ID: 17920365 [TBL] [Abstract][Full Text] [Related]
32. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. Wlodarczyk J; Sullivan D; Smith M Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019 [TBL] [Abstract][Full Text] [Related]
33. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction. Tungsubutra W; Phongtuntakul B J Med Assoc Thai; 2015 Feb; 98(2):129-36. PubMed ID: 25842792 [TBL] [Abstract][Full Text] [Related]
34. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. Betteridge DJ; Gibson JM Diabet Med; 2007 May; 24(5):541-9. PubMed ID: 17367312 [TBL] [Abstract][Full Text] [Related]
35. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Middleton A; Binbrek AS; Fonseca FA; Wilpshaar W; Watkins C; Strandberg TE Curr Med Res Opin; 2006 Jun; 22(6):1181-91. PubMed ID: 16846551 [TBL] [Abstract][Full Text] [Related]
36. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets. McCormack T; Harvey P; Gaunt R; Allgar V; Chipperfield R; Robinson P; Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050 [TBL] [Abstract][Full Text] [Related]
37. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy. Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554 [TBL] [Abstract][Full Text] [Related]
38. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome. Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632 [TBL] [Abstract][Full Text] [Related]
40. Cost effectiveness of rosuvastatin in treating patients to low-density lipoprotein cholesterol goals compared with atorvastatin, pravastatin, and simvastatin (a US Analysis of the STELLAR Trial). Miller PS; Smith DG; Jones P Am J Cardiol; 2005 Jun; 95(11):1314-9. PubMed ID: 15904635 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]